ReShape Lifesciences® announced the submission of a Premarket Approval (PMA) supplement application to the U.S. Food and Drug Administration (FDA) for the companyâs next generation, enhanced Lap-Band® 2.0, utilizing a band reservoir technology.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.2257 USD | +17.10% |
|
+13.99% | -9.61% |
15/05 | ReShape Lifesciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
15/05 | Transcript : ReShape Lifesciences Inc., Q1 2024 Earnings Call, May 15, 2024 |
1st Jan change | Capi. | |
---|---|---|
-9.61% | 52.93L | |
+0.91% | 20TCr | |
+3.74% | 18TCr | |
+28.89% | 15TCr | |
+31.66% | 11TCr | |
+1.37% | 6.42TCr | |
+19.45% | 5.49TCr | |
-2.27% | 4.67TCr | |
-9.28% | 3.68TCr | |
-0.10% | 3.53TCr |
- Stock Market
- Equities
- RSLS Stock
- News ReShape Lifesciences Inc.
- ReShape Lifesciences Submits FDA PMA Supplement Application for the Next-Generation Lap-Band® 2.0